Pharmaceuticals

Kidney Cancer Drugs Industry Overview 2025: Growth Projections and Market Trends

November 10, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

#What Are The Current (2025) And Forecast (2029) Sizes Of The Kidney Cancer Drugs Market?

The kidney cancer drugs market has experienced consistent expansion in recent years. It is anticipated to grow from $8.22 billion in 2024 to $8.53 billion in 2025, achieving a compound annual growth rate (CAGR) of 3.8%. This historical growth can be linked to factors such as rising healthcare spending, a quickly increasing elderly population, greater investment in pharmaceutical research and development, and advancements in the discovery of cancer treatments.

The kidney cancer drugs market size is expected to show steady growth in the coming years. It is projected to reach $10.31 billion in 2029, demonstrating a compound annual growth rate (CAGR) of 4.8%. The expansion during this forecast period can be attributed to factors such as an increasing geriatric population, a rise in healthcare expenditure, an increase in acquisitions and partnerships for drug development, and the high potential of emerging economies. Significant trends for the forecast period include adopting 3D technology in drug manufacturing and model creation, investing in biomarkers, launching or integrating new treatment developments, improving treatment through personalized medicine, investing in AI solutions, and collaborating and partnering with other companies or government bodies to accelerate the development of new drugs.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2591&type=smp

Which Drivers Are Shaping The Kidney Cancer Drugs Industry’s Market Share?

The increasing occurrence of renal cancer serves as a significant impetus for the kidney cancer drugs market. Lifestyle modifications, tobacco consumption, and unhealthy eating habits are some of the elements contributing to the proliferation of these renal cancer cells. For instance, in January 2022, according to the American Cancer Society, a US-based health organization dedicated to cancer elimination, there were projected to be 79,000 new kidney cancer diagnoses (including 50,290 men and 28,710 women), and 13,920 individuals were expected to die from the disease (comprising 8,960 men and 4,960 women). The majority of diagnoses occur between the ages of 65 and 74, with an average diagnosis age of 64. Kidney cancer is rather infrequent in individuals under the age of 45, thereby boosting the growth of the kidney cancer drugs market.

What Are The Different Segment Classifications Within The Kidney Cancer Drugs Market?

The kidney cancer drugs market covered in this report is segmented –

1) By Type: Renal Cell Carcinoma (RCC), Transitional Cell Carcinoma (TCC) Or Urothelial Cell Carcinoma (UCC)

2) By Product: Nexavar (Sorafenib), Sutent (Sunitinib), Afinitor (Everolimus), Votrient (Pazopanib), Avastin (Bevacizumab), Inlyta (Axitinib), Other Products

3) By End Users: Hospitals, Clinics, Research Center, Other End-Users

Subsegments:

1) By Renal Cell Carcinoma (RCC): Targeted Therapies, Immune Checkpoint Inhibitors, Cytokine Therapies

2) By Transitional Cell Carcinoma (TCC) Or Urothelial Cell Carcinoma (UCC): Chemotherapy Agents, Immunotherapy Agents, Antibody-Drug Conjugates (ADCs)

Which Market Trends Are Creating New Opportunities In The Kidney Cancer Drugs Industry?

Leading firms within the kidney cancer drug sector are prioritizing technological advancements, notably the creation of biosimilars, with the goal of expanding treatment alternatives, making therapies more accessible and cost-effective for patients, and speeding up breakthroughs in cancer treatment. This process involves manufacturing biological medications that closely mirror an existing, approved reference drug, guaranteeing equivalent effectiveness, safety, and standards. As an illustration, in November 2022, Amneal Pharmaceuticals Inc., a pharmaceutical firm based in the U.S., introduced RELEUKO (filgrastim-ayow). RELEUKO (filgrastim-ayow) is a biosimilar counterpart to Neupogen (filgrastim), also developed by Amneal Pharmaceuticals. Its purpose is to address neutropenia, especially in individuals receiving chemotherapy.

Which Major Firms Are Strengthening Their Position In The Kidney Cancer Drugs Industry?

Major companies operating in the kidney cancer drugs market include Pfizer Inc., Novartis AG, ExelixisInc., F. Hoffmann-La Roche AG, Bristol Myers Squibb Company, Bayer AG, Merck & Co., Inc., EUSA Pharma Inc., UroGen Pharma Ltd., Natco Pharma, CStone Pharma, CARsgen Therapeutics, JW Therapeutics, BeiGene, Takeda Pharmaceuticals, Astellas Pharma Inc, Otsuka Pharmaceutical Co., Ltd, Daiichi Pharmaceutical and Sankyo, AstraZeneca plc, GlaxoSmithKline plc, Amgen Inc ., Biocon Ltd, Rani Therapeutics, Eli Lilly and Company, Abbvie, Johnson & Johnson, Sanofi, Biogen Inc, AVEO Oncology, Teva Pharmaceutical Industries Ltd., Kitov Pharma Limited, CureTech Ltd., Neopharma

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/kidney-cancer-drugs-global-market-report

How Is Kidney Cancer Drugs Market Demand Varying Across Different Regions?

North America was the largest region in the kidney cancer drugs market in 2024. Middle East is expected to be the fastest-growing region in the global kidney cancer drugs market share during the forecast period. The regions covered in the kidney cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request A Customized Version Of The Kidney Cancer Drugs Market Report:

https://www.thebusinessresearchcompany.com/customise?id=2591&type=smp

Browse Through More Reports Similar to the Global Kidney Cancer Drugs Market 2025, By The Business Research Company

Diuretics Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/diuretics-drugs-global-market-report

Genito Urinary Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/genito-urinary-drugs-global-market-report

Dermatology Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/dermatology-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795